Skip to content

Sphenopalatine Block Versus Greater Occipital Nerve Block in PDPH

Lecturer of Anesthesia- Anesthesia Department Ain Shams University

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05235256
Enrollment
120
Registered
2022-02-11
Start date
2022-01-10
Completion date
2022-12-01
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Dural Puncture Headache

Brief summary

Management of postdural puncture headache (PDPH) has always been challenging for anesthesiologists. PDPH not only increases the misery of the patient, but the length of stay and overall cost of treatment in the hospital also increases. Although the epidural blood patch ( EBP ) is an effective way of treating the problem, the procedure itself could cause another inadvertent dural puncture (DP). Moreover, sometimes patients need to have a second EBP, if the first one is not completely effective. This can be difficult to explain to the patient who has already suffered a lot. Peripheral nerve blocks are well tolerated and effective as adjunctive therapy for many disabling headache disorder. Sphenopalatine ganglion is a parasympathetic ganglion, located in the pterygopalatine fossa. Transnasal sphenopalatine ganglion block ( SPGB ) has been successfully used to treat chronic conditions such as migraine, cluster headache, and trigeminal neuralgia, and may be a safer alternative to treat PDPH: It is minimally invasive and carried out at the bedside without using imaging. Besides that, it has apparently a faster start than EBP, with better safety profile. Another minimally invasive peripheral nerve block which has been used quite successful is greater occipital nerve block (GONB). The GONB has been in use for more than a decade to treat complex headache syndromes of varying etiologies like migraine , cluster headache and chronic daily headache with encouraging results. Greater Occipital Nerve (GON) arises from C2-3 segments, its most proximal part lies between obliqua capitis inferior and semispinalis, near the spinous process. Then, GON enters into semispinalis passing through it and after its exit; it enters into trapezius muscle. In distal region of trapezius fascia, it is crossed by the occipital artery and finally the nerve exits the trapezius fascia insertion into the nuchal line about 5-cm lateral to midline. Functionally, GON supplies major rectus capitis posterior muscle, and the skin, muscles, and vessels of the scalp, but is the main sensory supply of occipital region. Many providers believe that the local anesthetic produces the rapid onset of headache relief, like an abortive agent, and that the locally acting steroid produces the preventive like action of up to 6 weeks as dexamethasone possess potent anti inflammatory and immunosuppressive actions by inhibiting cytokine-mediated pathways .

Interventions

peripheral n block

bilateral greater occipital nerve block

DRUGlidocaine plus dexamethasone

lidocaine plus dexamethasone

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Obstetric patients ( American Society of Anesthesiologists ) ASA I&II ,body weight between 60-100kg expressing PDPH after spinal anesthesia, (VAS \> 4 ) with standard treatment such as intravenous fluids, abdominal binder, bed rest and caffeine.

Exclusion criteria

* • ASA III& IV patients. * Refusal of the patient. * Patients with chronic headache or migraine. * Hypertensive patients. * A patient that cannot comply with the VAS. * Infection at site of the block * Known coagulation defect. * Nasal septal deviation, polyp, history of nasal bleeding. * Allergy to local anaesthetics.

Design outcomes

Primary

MeasureTime frameDescription
Visual Analogue Score (VAS )first 24 hours after the procedureVisual A nalogue Scale will be used to asses the efficacy of either SPGB or GONB for treatment of PDPH .Score from 0 to 100 (0=no pain, 100=most severe pain)

Secondary

MeasureTime frameDescription
total analgesic consumptionfirst 24 hours after the blocktotal dose of ketorolac will be calculated

Countries

Egypt

Contacts

Primary Contactlecturer of anesthesia
rehab.fattah2002@gmail.com01110108610

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026